• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于生物利用度研究中评估药物吸收的新型血管外输入函数。

A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

作者信息

Weiss M

机构信息

Department of Pharmacology, Martin Luther University Halle-Wittenberg, Germany.

出版信息

Pharm Res. 1996 Oct;13(10):1547-53. doi: 10.1023/a:1016039931663.

DOI:10.1023/a:1016039931663
PMID:8899849
Abstract

PURPOSE

Flexible parametric models describing the input process after extravascular drug administration are needed for the assessment of absorption rate and the use of population methods in bioavailability and bioequivalence studies.

METHODS

The oral concentration-time curve modeled as the product of the input and disposition function in the Laplace domain was obtained by numerical inversion methods for parameter estimation. The utility of the inverse Gaussian input density was examined using bioavailability data of an extended-release dosage form. Measures of rate of absorption and the cumulative absorbed amount profile were defined in terms of the estimated model parameters.

RESULTS

Accurate estimation of absorption parameters was achieved by simultaneous fitting of the extravascular and intravascular data (describing the latter by a triexponential function). The new input function allowed a direct estimation of both extent of absorption and mean absorption time.

CONCLUSIONS

The findings suggest that the inverse Gaussian density is a useful input function. Its flexibility may reduce the effect of model misspecification in parameter estimation. All parameters can be readily interpreted in terms of the absorption process.

摘要

目的

在生物利用度和生物等效性研究中,评估吸收速率以及使用群体方法时,需要灵活的参数模型来描述血管外给药后的输入过程。

方法

通过数值反演方法获得拉普拉斯域中作为输入和处置函数乘积建模的口服浓度-时间曲线,用于参数估计。使用缓释剂型的生物利用度数据检验了逆高斯输入密度的实用性。根据估计的模型参数定义了吸收速率和累积吸收量曲线的度量。

结果

通过同时拟合血管外和血管内数据(用三指数函数描述后者)实现了吸收参数的准确估计。新的输入函数允许直接估计吸收程度和平均吸收时间。

结论

研究结果表明逆高斯密度是一种有用的输入函数。其灵活性可能会降低参数估计中模型错误指定的影响。所有参数都可以根据吸收过程轻松解释。

相似文献

1
A novel extravascular input function for the assessment of drug absorption in bioavailability studies.一种用于生物利用度研究中评估药物吸收的新型血管外输入函数。
Pharm Res. 1996 Oct;13(10):1547-53. doi: 10.1023/a:1016039931663.
2
DeMonS--a new deconvolution method for estimating drug absorbed at different time intervals and/or drug disposition model parameters using a monotonic cubic spline.DeMonS——一种使用单调三次样条估计不同时间间隔吸收的药物和/或药物处置模型参数的新去卷积方法。
Biopharm Drug Dispos. 1997 Aug;18(6):475-87. doi: 10.1002/(sici)1099-081x(199708)18:6<475::aid-bdd33>3.0.co;2-4.
3
Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.修订口服药物吸收的药代动力学:二、生物利用度-生物等效性的考虑。
Pharm Res. 2021 Aug;38(8):1345-1356. doi: 10.1007/s11095-021-03078-w. Epub 2021 Aug 2.
4
A note on population analysis of dissolution-absorption models using the inverse Gaussian function.关于使用逆高斯函数对溶解-吸收模型进行总体分析的说明。
J Clin Pharmacol. 2008 Jun;48(6):719-25. doi: 10.1177/0091270008315956. Epub 2008 Mar 21.
5
In vivo evaluation of the semi-simultaneous method for bioavailability estimation using controlled intravenous infusion as an 'extravascular' route of administration.
Biopharm Drug Dispos. 1991 Nov;12(8):583-97. doi: 10.1002/bdd.2510120805.
6
Measures of exposure versus measures of rate and extent of absorption.暴露量度与吸收速率及吸收程度量度
Clin Pharmacokinet. 2001;40(8):565-72. doi: 10.2165/00003088-200140080-00001.
7
Is the One-Compartment Model with First Order Absorption a Useful Approximation?具有一级吸收的单室模型是一种有用的近似模型吗?
Pharm Res. 2023 Sep;40(9):2147-2153. doi: 10.1007/s11095-023-03582-1. Epub 2023 Aug 18.
8
Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.通过半同步给药进行生物利用度估计:蒙特卡罗模拟研究
J Pharmacokinet Biopharm. 1990 Apr;18(2):103-20. doi: 10.1007/BF01063554.
9
Pharmacokinetics of oral extended-release dosage forms. I. Release kinetics, concentration, and absorbed fraction.
Pharm Res. 1995 May;12(5):720-8. doi: 10.1023/a:1016215827004.
10
Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil.
J Pharmacokinet Biopharm. 1992 Oct;20(5):421-42. doi: 10.1007/BF01061464.

引用本文的文献

1
Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables.抗体及长效注射剂皮下/肌肉注射吸收的扩散维度建模
J Pharmacokinet Pharmacodyn. 2025 Apr 22;52(3):26. doi: 10.1007/s10928-025-09973-8.
2
Dependence of Bioavailability on Mean Absorption Time: What Does It Tell Us?生物利用度对平均吸收时间的依赖性:它告诉了我们什么?
AAPS J. 2023 Apr 4;25(3):36. doi: 10.1208/s12248-023-00803-8.
3
Semi-mechanistic reduced order model of pharmaceutical tablet dissolution for enabling Industry 4.0 manufacturing systems.

本文引用的文献

1
Limitations of the maximum entropy principle in devising drug input rate.最大熵原理在设计药物输入速率方面的局限性。
Eur J Clin Pharmacol. 1995;49(1-2):139-43. doi: 10.1007/BF00192372.
2
A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples.一种用于去卷积的非参数个体特异性总体方法:I. 描述、内部验证及实际数据示例
J Pharmacokinet Biopharm. 1995 Dec;23(6):581-610. doi: 10.1007/BF02353463.
3
Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.
用于实现工业 4.0 制造系统的药物片剂溶出的半机械简化模型。
Int J Pharm. 2023 Jan 25;631:122502. doi: 10.1016/j.ijpharm.2022.122502. Epub 2022 Dec 16.
4
Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin.多次给药后的复杂吸收分析:在 P-糖蛋白底物他林洛尔和利福平相互作用中的应用。
Pharm Res. 2022 Dec;39(12):3293-3300. doi: 10.1007/s11095-022-03397-6. Epub 2022 Sep 26.
5
Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with : A Study on Population Pharmacokinetics with Monte Carlo Simulations.口服罗可替尼(司立西利)在慢性感染的囊性纤维化患者中的非线性药代动力学:一项基于蒙特卡洛模拟的群体药代动力学研究
Pharmaceutics. 2020 Nov 12;12(11):1087. doi: 10.3390/pharmaceutics12111087.
6
Clofazimine pharmacokinetics in patients with TB: dosing implications.氯法齐明在结核病患者中的药代动力学:给药的影响。
J Antimicrob Chemother. 2020 Nov 1;75(11):3269-3277. doi: 10.1093/jac/dkaa310.
7
A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.一种用于药代动力学和药效学研究中延迟结局建模的分布式延迟方法。
J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):285-308. doi: 10.1007/s10928-018-9570-4. Epub 2018 Jan 24.
8
Empirical models for fitting of oral concentration time curves with and without an intravenous reference.用于拟合有无静脉内参比情况下口服浓度-时间曲线的经验模型。
J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):193-201. doi: 10.1007/s10928-017-9507-3. Epub 2017 Feb 1.
9
Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects.基于模型评估制剂和食物摄入对健康受试者中吗氯贝胺复杂口服吸收的影响。
Pharm Res. 2015 May;32(5):1764-78. doi: 10.1007/s11095-014-1574-1. Epub 2014 Nov 26.
10
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.伏立康唑对肝和肠壁细胞色素 P4503A 动态抑制的拟生理群体药代动力学模型。
Clin Pharmacokinet. 2013 Sep;52(9):763-81. doi: 10.1007/s40262-013-0070-9.
Eur J Clin Pharmacol. 1993;44(3):231-5. doi: 10.1007/BF00271363.
4
A Weibull distribution model for intradermal administration of ceftazidime.
J Pharm Sci. 1993 Nov;82(11):1175-8. doi: 10.1002/jps.2600821123.
5
Bioequivalence: performance of several measures of rate of absorption.生物等效性:几种吸收速率测量指标的表现
Pharm Res. 1994 Jul;11(7):966-74. doi: 10.1023/a:1018970901116.
6
Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".生物等效性研究中评估“速率”的间接指标的敏感性——移动“球门柱”还是改变“游戏规则”。
J Pharm Sci. 1994 Nov;83(11):1554-7. doi: 10.1002/jps.2600831107.
7
A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate.
J Pharm Sci. 1994 Oct;83(10):1461-4. doi: 10.1002/jps.2600831019.
8
Accuracy of numerical inversion of Laplace transforms for pharmacokinetic parameter estimation.用于药代动力学参数估计的拉普拉斯变换数值反演的准确性。
J Pharm Sci. 1995 Jan;84(1):71-4. doi: 10.1002/jps.2600840117.
9
Estimating bioavailability when clearance changes in time: the effect of model misspecification.
Clin Pharmacol Ther. 1995 Nov;58(5):595-600. doi: 10.1016/0009-9236(95)90181-7.
10
Pharmacokinetics of oral extended-release dosage forms. I. Release kinetics, concentration, and absorbed fraction.
Pharm Res. 1995 May;12(5):720-8. doi: 10.1023/a:1016215827004.